Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Antihypertensive Drugs Market $19 Billion by 2027

The global market for antihypertensive drugs expected to reach $19 billion by 2027, steadily declining at CAGR 0.8% over the forecast period, driven by patent expiration of blockbuster drugs, increasing generic competition and continued cost-containment pressures on healthcare providers.

Global Antihypertensive Drugs Market

Hypertension is the leading preventable cause of premature death worldwide. It is an important public health challenge in both economically developing and developed countries.


The worldwide prevalence of hypertension is estimated to be about 40% in all adults, represented a 5.2% increase in the global prevalence between 2000 and 2010.

  • The prevalence of hypertension decreased by 2.6% in high-income countries, but increased by 7.7% in low/middle–income countries due to numerous and varied obstacles in healthcare delivery and limited resources.
    • Measures are required to prevent the development of hypertension and to improve awareness, treatment and control of hypertension globally.

Antihypertensive drugs are used to treat high blood pressure and its complications, such as stroke and myocardial infarction.

The most important and most widely used drugs include thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta blockers. These drugs can prevent heart failure, kidney failure and acute stroke induced by hypertension and delay the development of atherosclerosis by controlling the blood pressure.

  • Although clinical evidence shows calcium channel blockers and thiazide-type diuretics are preferred first-line treatments, an ACE inhibitor is recommended by NICE in the UK for those under 55 years old.
  • Angiotensin II receptor blockers (ARBs) comprises several leading brands such as Benicar (olmesartan medoxomil), Diovan (valsartan) and Micardis (telmisartan).
  • The ‘others’ category includes endothelin receptor antagonists such as Tracleer, Opsumit (bosentan and macitentan) and Letairis (ambrisentan). All drug classes, except fixed-dose combinations (FDCs), represent sales of monotherapies.
  • Some of the antihypertensive drugs currently in the phase III clinical development include mono-therapies and fixed-dose combinations such as Amlodipine/celecoxib, Azilsartan/amlodipine/ hydrochlorothiazide, Bardoxolone methyl, Candesartan cilexetil/nifedipine, Candesartan cilexetil/rosuvastatin, CS 3150, Esuberaprost, Fimasartan/amlodipine, Fimasartan/hydrochlorothiazide, HCP 1401 and HCP1305, Nitric oxide inhalation (INOpulse), Telmisartan/amlodipine/ chlorthalidone, Telmisartan/chlorthalidone, alsartan/amlodipine/rosuvastatin, and Valsartan/pitavastatin.

The global antihypertensive drugs market research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).

The global antihypertensive drugs market is segmented by drug class (product/brand) – angiotensin II receptor blockers [Olmesartan medoxomil (Benicar, Olmetec), Valsartan (Diovan, Byvalson), Telmisartan (Micardis), Irbesartan (Aprovel, Avapro), Candesartan cilexetil (Atacand, Blopress)], angiotensin-converting enzyme inhibitors [Captopril (Capoten), Lisinopril (Prinivil, Zestril), Fosinopril (Monopril)], beta-blockers [Atenolol (Tenormin), Metoprolol Succinate (Lopressor, Metolar XR, Seloken, Toprol XL), Carvedilol (Coreg), Nadolol (Corgard), Propranolol (Inderal)], calcium channel blockers [Amlodipine (Norvasc), Nifedipine (Adalat, Procardia)], thiazide diuretics [Hydrochlorothiazide (Aquazide, Apo-Hydro, Dyazide, BPZide), Chlorthalidone (Hygroton, Thalitone, Clorpres)], fixed-dose combinations [Olmesartan & Amlodipine (Azor), Valsartan & Amlodipine (Exforge), Losartan & Hydrochlorothiazide (Cozaar/Hyzaar), Amlodipine & Benazepril (Lotrel)], and others and geography. 

  • Based on drug classes, the angiotensin II receptor blockers (ARBs) segment accounted for the largest share of the total hypertension market, however it is predicted to reduce in size to almost half, over the coming years.
    • The calcium channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors segments expected to follow a similar pattern as ARBs in the near future.
    • On the other hand, the drugs in the others category segment are expected to witness the largest revenue share by the end of forecast period.
  • The beta-blockers segment to show positive growth rate over the forecast period.
  • The fixed-dose combinations (FDCs) and thiazide diuretics segments anticipated to grow steadily throughout the next few years.
    • According to a draft published by the US FDA, the FDC antihypertensives segment focusing on two-drug combinations of previously-approved drugs, with reasonably distinct mechanisms of action are likely to demonstrate additive blood pressure effects.
      • In addition, if combinations include doses of each drug below the maximum dose, dose-related adverse effects of the components can be expected to be reduced.

The global antihypertensive drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for antihypertensive drugs and profiled in this report include Alvogen, AstraZeneca plc, Bayer AG, Bellerophon Therapeutics, Inc., Boehringer Ingelheim GmbH, Boryung Pharmaceutical Co.,Ltd., Bristol-Myers Squibb and Company, Daiichi Sankyo Company, Gilead Sciences, Inc., Eli Lilly and Company, HanAll Biopharma Co., Ltd., Hanmi Pharmaceutical Co., Ltd., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), JW Pharmaceutical Corporation (Choongwae Pharma) , Kyowa Kirin Co., Ltd., Lung Biotechnology PBC, Merck & Co., Inc., Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer, Inc., Purple Biotech (Kitov Pharmaceuticals), Sanofi SA, Servier Laboratories, Stendhal Pharma, Reata Pharmaceuticals, Inc., Takeda Pharmaceutical Co., Ltd., United Therapeutics Corporation, and Yuhan Co, Ltd.

  • Drug Class (Product/Brand)
    • Angiotensin II Receptor Blockers (ARBs)
      • Olmesartan medoxomil (Benicar, Olmetec)
      • Valsartan (Diovan, Byvalson)
      • Telmisartan (Micardis)
      • Irbesartan (Aprovel, Avapro)
      • Candesartan cilexetil (Atacand, Blopress)
      • Other ARBs
    • Angiotensin-Converting Enzyme Inhibitors (ACEIs)
      • Captopril (Capoten)
      • Lisinopril (Prinivil, Zestril)
      • Fosinopril (Monopril)
      • Other ACEIs
    • Beta-Blockers
      • Atenolol (Tenormin)
      • Metoprolol Succinate (Lopressor, Metolar XR, Seloken, Toprol XL)
      • Carvedilol (Coreg)
      • Nadolol (Corgard)
      • Propranolol (Inderal)
      • Other BBs
    • Calcium Channel Blockers (CCBs)
      • Amlodipine (Norvasc)
      • Nifedipine (Adalat, Procardia)
      • Other CCBs
    • Thiazide Diuretics (TDs)
      • Hydrochlorothiazide (Aquazide, Apo-Hydro, Dyazide, BPZide)
      • Chlorthalidone (Hygroton, Thalitone, Clorpres)
      • Other TDs
    • Fixed-Dose Combinations (FDCs)
      • Olmesartan & Amlodipine (Azor)
      • Valsartan & Amlodipine (Exforge)
      • Losartan & Hydrochlorothiazide (Hyzaar)
      • Amlodipine & Benazepril (Lotrel)
      • Other FDCs
    • Other Drugs
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Alvogen
    • AstraZeneca plc
    • Bayer AG
    • Bellerophon Therapeutics, Inc.
    • Boehringer Ingelheim GmbH
    • Boryung Pharmaceutical Co.,Ltd.
    • Bristol-Myers Squibb and Company
    • Daiichi Sankyo Company
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • HanAll Biopharma Co., Ltd.
    • Hanmi Pharmaceutical Co., Ltd.
    • Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
    • JW Pharmaceutical Corporation (Choongwae Pharma)
    • Kyowa Kirin Co., Ltd.
    • Lung Biotechnology PBC
    • Merck & Co., Inc.
    • Nippon Shinyaku Co. Ltd.
    • Novartis AG
    • Pfizer, Inc.
    • Purple Biotech (Kitov Pharmaceuticals)
    • Sanofi SA
    • Servier Laboratories
    • Stendhal Pharma
    • Reata Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Co., Ltd.
    • United Therapeutics Corporation
    • Yuhan Co, Ltd.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]